CAMBRIDGE, Mass.--(BUSINESS WIRE)--Relay Therapeutics, a biotech company dedicated to developing breakthrough medicines by leveraging insights from protein motion, today announced the appointment of Sarah O’Brien as Vice President of Human Resources. O’Brien joins Relay Therapeutics with significant strategic human resources experience in the life sciences industry.
“We are excited to have Sarah join the Relay team,” said Sanjiv Patel, President & Chief Executive Officer at Relay Therapeutics. “Sarah brings with her valuable insights that can be applied to continue advancing our commitment to advancing drug discovery and developing our team. We look forward to her working across the organization to guide Relay’s growth while ensuring that we retain our strong commitment to both our people and culture and remain true to our core values.”
Prior to joining Relay, O’Brien led Human Resources for Swedish Orphan Biovitrum AB (Sobi), in North America and was responsible for a variety of global initiatives across learning, development and culture for Sobi. Prior to Sobi, O’Brien spent seven years working at Novartis for Novartis Vaccines and then with the Novartis Institute for Biomedical Research (NIBR). At NIBR, O’Brien worked closely with the translational medicine, oncology and immunotherapy organizations. O’Brien graduated summa cum laude from the University of New Hampshire with a B.A. in English, Philosophy and Art History.
“I am thrilled to join this exceptional team that has a strong culture and compelling scientific approach,” said O’Brien. “I am passionate about supporting growth and development at Relay so that we can create medicines with meaningful clinical impact.”
About Relay Therapeutics
Relay Therapeutics is committed to discovering and developing medicines that will make a transformative difference for patients by building the first dedicated drug discovery pipeline centered on protein motion. Bringing together the latest scientific advances in structural biology, biophysics, computation, chemistry and biology, Relay’s drug discovery engine illuminates the full mobility of a protein and the ways in which protein motion regulates function. By applying this approach and by focusing on disease-causing targets, Relay aims to develop breakthrough medicines for patients in need. The company’s initial programs are focused on developing therapeutics in oncology. Headquartered in Cambridge, Massachusetts, Relay Therapeutics is a private company launched in 2016 with $57 million in Series A financing from Third Rock Ventures and an affiliate of D. E. Shaw Research.